» Articles » PMID: 38114929

Long Non-coding RNA SNHG4 Aggravates Cigarette Smoke-induced COPD by Regulating MiR-144-3p/EZH2 Axis

Overview
Journal BMC Pulm Med
Publisher Biomed Central
Specialty Pulmonary Medicine
Date 2023 Dec 20
PMID 38114929
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: The purpose of this study was to explore the expression level of SNHG4 in patients with COPD and its diagnostic value in COPD, to probe the biological function of SNHG4 in COPD at the cellular level, and to reveal the interaction between SNHG4 and miR-144-3p/EZH2 axis.

Methods: The serum levels of SNHG4, miR-144-3p and EZH2 in healthy people and patients with COPD were detected by RT-qPCR. The diagnostic value of SNHG4 in COPD was evaluated by ROC curve. Pearson method was chosen to estimate the correlation between SNHG4 and clinical indicators in patients with COPD. Cigarette smoke extract (CSE) was obtained, and Beas-2B cells were exposed with 2% CSE to establish an inflammatory cell model of COPD in vitro. MTT assay was used to detect cell viability, flow cytometry was used to evaluate cell apoptosis, and ELISA was performed to detect inflammatory cytokines. Dual-luciferase reporting assay was carried out to verify the targeting of lncRNA-miRNA or miRNA-mRNA.

Results: (1) The expression of SNHG4 is decreased in patients with COPD, and the expression level in acute exacerbation COPD was lower than that in stable COPD. SNHG4 demonstrated high diagnostic accuracy in distinguishing between stable and acute exacerbation COPD. (2) The expression of SNHG4 was decreased in CSE-induced Beas-2B cells, and overexpression of SNHG4 was beneficial to alleviate CSE-induced apoptosis and inflammation. (3) The expression of miR-144-3p is up-regulated in patients with COPD and CSE-induced Beas-2B cells. MiR-144-3p has a targeting relationship with SNHG4, which is negatively regulated by SNHG4. Overexpression of miR-144-3p could counteract the beneficial effects of increased SNHG4 on CSE-induced cells. (4) The expression of EZH2 is reduced in patients with COPD and CSE-induced Beas-2B cells. Bioinformatics analysis and luciferase reporter gene confirmed that EZH2 is the downstream target gene of miR-144-3p and is negatively regulated by miR-144-3p.

Conclusion: The expression of SNHG4 decreased in patients with COPD, and it may promote the progression of COPD by inhibiting the viability, promoting apoptosis and inflammatory response of bronchial epithelial cells via regulating the miR-144-3p/EZH2 axis.

Citing Articles

The Role of miR-144 in Inflammatory Diseases: A Review.

Hong S, Wang H, Qiao L Immun Inflamm Dis. 2025; 13(3):e70172.

PMID: 40067024 PMC: 11894823. DOI: 10.1002/iid3.70172.


Dietary Zinc activates the Nrf2 signaling pathway to inhibit pyroptosis and attenuate the lung inflammatory response in COPD.

Huang Y, Liang T, Liu J, Yu H, Li J, Han L Cytotechnology. 2025; 77(2):62.

PMID: 39980839 PMC: 11836256. DOI: 10.1007/s10616-025-00725-7.

References
1.
Chen L, Heikkinen L, Wang C, Yang Y, Sun H, Wong G . Trends in the development of miRNA bioinformatics tools. Brief Bioinform. 2018; 20(5):1836-1852. PMC: 7414524. DOI: 10.1093/bib/bby054. View

2.
Tang Y, Wu L, Zhao M, Zhao G, Mao S, Wang L . promotes the proliferation, migration, invasiveness, and epithelial-mesenchymal transition of lung cancer cells by regulating . Biochem Cell Biol. 2019; 97(6):767-776. DOI: 10.1139/bcb-2019-0065. View

3.
Hu W, Ding Y, Wang S, Xu L, Yu H . The Construction and Analysis of the Aberrant lncRNA-miRNA-mRNA Network in Adipose Tissue from Type 2 Diabetes Individuals with Obesity. J Diabetes Res. 2020; 2020:3980742. PMC: 7168724. DOI: 10.1155/2020/3980742. View

4.
Lago J, Toledo-Arruda A, Mernak M, Barrosa K, Martins M, Tiberio I . Structure-activity association of flavonoids in lung diseases. Molecules. 2014; 19(3):3570-95. PMC: 6271797. DOI: 10.3390/molecules19033570. View

5.
Wei J, Wu C, Chen J, Shang F, Guo S, Zhang X . LncRNA NEAT1 promotes the progression of sepsis-induced myocardial cell injury by sponging miR-144-3p. Eur Rev Med Pharmacol Sci. 2020; 24(2):851-861. DOI: 10.26355/eurrev_202001_20069. View